Mirae Asset Global Investments Co. Ltd. lowered its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 22.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 289,466 shares of the company's stock after selling 85,296 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in AstraZeneca were worth $21,344,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dynamic Advisor Solutions LLC lifted its stake in AstraZeneca by 58.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock valued at $960,000 after acquiring an additional 4,811 shares during the period. Geode Capital Management LLC grew its stake in AstraZeneca by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock valued at $32,683,000 after acquiring an additional 5,384 shares during the period. Dorsey & Whitney Trust CO LLC raised its position in shares of AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock worth $2,313,000 after purchasing an additional 189 shares during the last quarter. Brandywine Global Investment Management LLC purchased a new position in AstraZeneca in the 4th quarter valued at about $28,071,000. Finally, Farther Finance Advisors LLC increased its stake in AstraZeneca by 13.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after buying an additional 706 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Separately, BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, AstraZeneca has an average rating of "Moderate Buy" and an average target price of $85.00.
View Our Latest Research Report on AZN
AstraZeneca Stock Down 0.5%
Shares of NASDAQ AZN traded down $0.32 during midday trading on Wednesday, hitting $71.14. 2,976,850 shares of the company's stock were exchanged, compared to its average volume of 5,226,692. The firm's fifty day simple moving average is $70.72 and its 200-day simple moving average is $70.56. The company has a market cap of $220.62 billion, a PE ratio of 28.57, a P/E/G ratio of 1.28 and a beta of 0.37. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the firm earned $2.06 EPS. The company's revenue was up 7.2% compared to the same quarter last year. Research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
